Po-Lin Chen

Po-Lin Chen

Auto-generated profile, based on publicly available information

Po-Lin Chen

Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
PDF file
TKTzu-Ting Kuo
Tzu-Ting Kuo
PCPo-Lin Chen
Po-Lin Chen
CSChun-Che Shih
Chun-Che Shih
ICI-Ming Chen
I-Ming Chen
Superior vena cava (SVC) syndrome comprises a group of signs and symptoms secondary to SVC obstruction. Obstruction occurs when venous return from the SVC to the right atrium is compromised, mostly by a growing malignancy compressing the SVC extrinsically.1, 2, 3, 4, 5 In the absence of adequate collaterals, the resulting elevated venous pressure in the upper body leads to edema of the head, neck, and upper extremities. Rarely, swelling of the larynx may cause life-threatening airway obstruction and cerebral edema, which can result in confusion and coma. While treatment of underlying malignant disease is paramount, it may be slow to alleviate the patient's discomfort. In some radiosensitive malignancies, radiotherapy may effectively reduce symptoms by reducing the tumor size,3, 6 but this process can take weeks to months and has a higher recurrence rate. The increasing technical and clinical success rate of SVC stenting makes it another option for salvage therapy after conventional radiochemotherapy has failed. In fact, Ganeshan et al. suggested that primary SVC stenting should be the first-line treatment to relieve the symptoms of SVC syndrome.4 The aim of the present study was to review our SVC stenting experience retrospectively in order to validate the safety, effectiveness, and outcomes of salvage and primary stenting for malignant SVC obstruction.

1 March 2018 in Medicine
Verified
Journal Article
Open access
CCChing-Shu Chiang
Ching-Shu Chiang
PCPo-Lin Chen
Po-Lin Chen
TKTzu-Ting Kuo
Tzu-Ting Kuo
ICI-Ming Chen
I-Ming Chen
NWNai-Yuan Wu
Nai-Yuan Wu
HCHsiao-Huang Chang
Hsiao-Huang Chang
Intravascular leiomyomatosis (IVL) is a rare nonmalignant tumor that can be fatal if untreated. A 49-year-old nulliparous Asian woman who underwent hysterectomy and left salpingo-oophorectomy for multiple uterine leiomyomas 18 months prior presented complaining of intermittent palpitation and chest tightness for approximately 1 month. Echocardiography revealed a large mobile tumor mass extending from the inferior vena cava (IVC) to the right atrium that partially obstructed IVC flow and tricuspid inflow. Thoracicabdominopelvic computed tomography revealed a left adnexal tumor (4.8 × 2.5 cm) causing intravascular obstruction extending from the left internal iliac vein to the IVC, right atrium, and right ventricle. IVL with right heart involvement INTERVENTIONS:: Under cardiopulmonary bypass, a one-stage surgery combining sternotomy and laparotomy was performed. The tumor was approached and extracted via sternotomy, and tumor detachment and removal of residual tumors was accomplished via laparotomy. A firm, smooth, and regularly shape tumor 15.5 × 5.5 × 2.5 in size was completely removed and histopathologically confirmed as IVL. The patient tolerated the surgical procedure well and no postoperative complication was noted. We describe a one-stage surgical approach to completely remove an IVL extending to the right ventricle.

1 March 2005 in Diamond and Related Materials
Verified
Journal Article
Closed access
PCPo-Lin Chen
Po-Lin Chen
JCJun-Kai Chang
Jun-Kai Chang
FPFu-Ming Pan
Fu-Ming Pan
CKCheng-Tzu Kuo
Cheng-Tzu Kuo

29 January 2022 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
HHHung-Lung Hsu
Hung-Lung Hsu
CHChun-Yang Huang
Chun-Yang Huang
HLHsin-Ying Lu
Hsin-Ying Lu
CHChiao-Po Hsu
Chiao-Po Hsu
PCPo-Lin Chen
Po-Lin Chen
CSChun-Che Shih
Chun-Che Shih
Data about volumetric remodeling of the provisional extension to induce complete attachment (PETTICOAT) technique on DeBakey type IIIb aortic dissection in acute and subacute phases were scarce. The proper timing to perform this technique to promote false lumen reduction was also unknown. Patients with DeBakey type IIIb aortic dissection who underwent the PETTICOAT technique between December 2005 and March 2017 were reviewed and divided into acute (treatment occurred ≦14 days after symptom onset) and subacute (15-90 days) groups. Remodeling parameters of the true and false lumens were analyzed. Receiver operating characteristic curve was used to deduce the timing of this technique. In the 2-year follow-up, the acute group (N = 20) demonstrated significant true lumen expansion and false lumen regression in the thoracic, abdominal, and total aorta. However, the subacute group (N = 20) only showed significant shrinkage in the false lumen of the thoracic and total aorta. Using PETTICOAT technique within 36 days after the aortic event may result in better total false lumen reduction. For DeBakey type IIIb aortic dissection, more prominent true lumen expansion and false lumen reduction were noted when using the PETTICOAT technique in the acute phase. When performed within 36 days after symptoms onset, the PETTICOAT technique may potentiate better total false lumen regression.

21 December 2020 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
CHChun-Yang Huang
Chun-Yang Huang
PCPo-Lin Chen
Po-Lin Chen
HLHsin-Ying Lu
Hsin-Ying Lu
HHHung-Lung Hsu
Hung-Lung Hsu
TKTzu-Ting Kuo
Tzu-Ting Kuo
CSChun-Che Shih
Chun-Che Shih
OBJECTIVES: Although commercial iliac branch devices offer a new and valid endovascular approach to treating iliac aneurysm and effectively preserve antegrade flow of the internal iliac artery, their use may not be suited for all types of challenging anatomy, especially isolated common iliac artery aneurysm. Our custom-made iliac bifurcation device has a unique design and excludes both combined and isolated iliac branch aneurysm. This study validated the efficacy and safety of the custom device by comparing clinical outcomes between groups receiving commercial and custom devices. METHODS: Data of consecutive patients receiving iliac bifurcation device implantation for iliac aneurysm with or without concomitant endovascular repair for abdominal aortic aneurysm from January 2010 to May 2019 were reviewed. RESULTS: Iliac bifurcation device implantation with or without concomitant abdominal aortic aneurysm stent grafting was completed in 46 patients (commercial, n = 35; custom, n = 11). No significant differences were observed regarding postoperative complications, occlusion or endoleak. Comparisons of primary (80.8% vs 85.7%, P = 0.88) and secondary (86.5% vs 85.7%, P = 0.85) patency and freedom from reintervention (88.2% vs 100%, P = 0.33), all-cause mortality (78.6% vs 100%, P = 0.25) and aneurysm-related mortality (100% vs 100%, P = 1.00) also indicated no differences at a 5-year surveillance point. Furthermore, the iliac aneurysms of the groups displayed similar shrinkage 1 year after procedures. CONCLUSIONS: For iliac aneurysm, the novel custom-made iliac bifurcation device is an adaptable design not inferior to commercial devices with regard to postoperative complications, bridge occlusion, endoleak and short-term aneurysm remodelling. It provides an alternative for treatment, particularly when certain anatomic challenges are present. Clinical trial registration: 2018-07-050BC, 2017-01-023ACF.

22 July 2017 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
WCWan-Chi Chiang
Wan-Chi Chiang
EPEmily Ling-Lin Pai
Emily Ling-Lin Pai
PCPo-Lin Chen
Po-Lin Chen
CSChun-Che Shih
Chun-Che Shih
ICI-Ming Chen
I-Ming Chen